EVALUATION OF ADHERENCE TO BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH INFLAMMATORY ARTHRITIS

被引：0
|
作者：
Lim, Y. C. [1 ]
Teo, W. G. [2 ]
Eng, M. N. [1 ]
Cheen, H. M. [1 ]
Tay, X. Y. [1 ]
Yeo, S. I. [3 ]
Lim, T. G. [1 ]
机构：
[1] Singapore Gen Hosp, Pharm, Singapore, Singapore
[2] Natl Heart Ctr Singapore, Pharm, Singapore, Singapore
[3] Singapore Gen Hosp, Rheumatol & Immunol, Singapore, Singapore
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
RHEUMATOID-ARTHRITIS;
D O I：
10.1136/annrheumdis-2018-eular.2183
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0748-HP
引用
收藏
页码：1800 / 1800
页数：1
相关论文
共 50 条
  • [31] Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs
    Hanaoka, Hironari
    Kikuchi, Jun
    Hiramoto, Kazuoto
    Saito, Shuntaro
    Kondo, Yasushi
    Kaneko, Yuko
    CLINICAL KIDNEY JOURNAL, 2022, 15 (07) : 1373 - 1378
  • [32] EFFICACY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS STRATIFIED BY NUMBER OF PRIOR BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    Mease, P. J.
    Lertratanakul, A.
    Strober, B.
    Tsuji, S.
    Richette, P.
    Lovan, C.
    Feng, D.
    Anderson, J.
    Van den Bosch, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 788 - 789
  • [33] Effect of biologic disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis who hope to become mothers
    Hiromi Shimada
    Tomohiro Kameda
    Kenji Kanenishi
    Nobuyuki Miyatake
    Shusaku Nakashima
    Risa Wakiya
    Mikiya Kato
    Taichi Miyagi
    Mai Mahmoud Fahmy Mansour
    Toshiyuki Hata
    Norimitsu Kadowaki
    Hiroaki Dobashi
    Clinical Rheumatology, 2019, 38 : 1453 - 1458
  • [34] Efficacy of Upadacitinib in Patients with Psoriatic Arthritis Stratified by Number of Prior Biologic Disease-modifying Anti-rheumatic Drugs
    Mease, Philip
    Lertratanakul, Apinya
    Strober, Bruce
    Tsuji, Shigeyoshi
    Richette, Pascal
    Lovan, Charlie
    Feng, Dai
    Anderson, Jaclyn K.
    Van den Bosch, Filip
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [35] Cardiovascular Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
    Drakopoulou, Maria
    Soulaidopoulos, Stergios
    Oikonomou, George
    Tousoulis, Dimitrios
    Toutouzas, Konstantinos
    CURRENT VASCULAR PHARMACOLOGY, 2020, 18 (05) : 488 - 506
  • [36] RHEUMATOID-ARTHRITIS - DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    KIRWAN, JR
    CURREY, HLF
    CLINICS IN RHEUMATIC DISEASES, 1983, 9 (03): : 581 - 599
  • [37] Combination therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis
    Garrood, T
    Scott, DL
    BIODRUGS, 2001, 15 (08) : 543 - 561
  • [38] Combination Therapy with Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis
    Toby Garrood
    David L. Scott
    BioDrugs, 2001, 15 : 543 - 561
  • [39] Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
    Agarwal, S.
    Zaman, T.
    Handa, R.
    SINGAPORE MEDICAL JOURNAL, 2009, 50 (07) : 686 - 692
  • [40] Trajectories of Adherence to Biologic Disease-Modifying Anti-Rheumatic Drugs in Tuscan Administrative Databases: The Pathfinder Study
    Convertino, Irma
    Giometto, Sabrina
    Gini, Rosa
    Cazzato, Massimiliano
    Fornili, Marco
    Valdiserra, Giulia
    Cappello, Emiliano
    Ferraro, Sara
    Bartolini, Claudia
    Paoletti, Olga
    Tillati, Silvia
    Baglietto, Laura
    Turchetti, Giuseppe
    Trieste, Leopoldo
    Lorenzoni, Valentina
    Blandizzi, Corrado
    Mosca, Marta
    Tuccori, Marco
    Lucenteforte, Ersilia
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (24)
12345